# Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

> **NCT05932641** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- COVID-19, SARS-CoV-2

## Interventions

- **BIOLOGICAL:** AZD3152 (Cohort 1)
- **BIOLOGICAL:** Placebo (Cohort 1)
- **BIOLOGICAL:** AZD3152 (Cohort 2)
- **BIOLOGICAL:** Placebo (Cohort 2)
- **BIOLOGICAL:** AZD3152 (Cohort 3)
- **BIOLOGICAL:** Placebo (Cohort 3)

## Key facts

- **NCT ID:** NCT05932641
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-31
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932641, "Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05932641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*